Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

Summary: Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, t...

Full description

Bibliographic Details
Main Authors: Kathleen W. Zhang, MD, Keith E. Stockerl-Goldstein, MD, Daniel J. Lenihan, MD
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:JACC: Basic to Translational Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X19300567

Similar Items

Similar Items